Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Neuro-OncologyOpen Access

Transforming Molecular Neuropathology for Brain Tumour Patients in the Uk: Lessons From the Tessa Jowell Centre of Excellence Programme

View Full Paper
Ask AI
Bookmark
Share

Authors

AWAndrew Jordan WrightFSFereshteh SariCGCamille Goetz

Discussion

Loading...

Member takes

Overview

National review highlights significant growth in genomic testing for brain tumours, indicating ongoing inequalities.

Key Points

  • Overall genetic testing for brain tumours more than doubled from 2021 to 2024, yet disparities persist.
  • From 2021 to 2024, the average turnaround time for integrated diagnosis increased by 31%, reflecting inconsistencies.
  • National review involved 21 UK neuro-oncology centres, assessing standards based on 22 expert guidelines.
  • Collaboration with stakeholders aims to address ongoing challenges in molecular neuropathology testing.

Cite This Study

Wright et al. (2025) studied this question.

synapsesocial.com/papers/68c23abeb210217d64781474https://doi.org/10.1093/neuonc/noaf185.007
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P17.48.B TRANSFORMING MOLECULAR NEUROPATHOLOGY FOR ADULT BRAIN TUMOUR PATIENTS IN THE UK: INSIGHTS FROM THE TESSA JOWELL CENTRE OF EXCELLENCE PROGRAMME (2021-2024)2025
  2. 2BRAIN TUMOUR RESEARCH AND CLINICAL TRIALS ACTIVITY IN THE UK 2016-2024: INSIGHTS FROM THE TESSA JOWELL CENTRE OF EXCELLENCE PROGRAMME2025
  3. 3P05.27.A INTRODUCTION OF WHOLE GENOME SEQUENCING AS NHS STANDARD OF CARE FOR GLIOMA PATIENTS IN TWO NEUROSURGICAL CENTRES: WEST MIDLANDS2025
  4. 4A SERVICE EVALUATION OF WHOLE GENOME SEQUENCING IN PRIMARY BRAIN TUMOURS AT A TERTIARY UK NEURO-ONCOLOGY CENTRE: CLOSING THE GAPS2025
  5. 5P17.46.B CLINICAL FEATURES AND MOLECULAR PROFILING USING NEXT GENERATION SEQUENCING AMONG GLIOMA PATIENTS: RETROSPECTIVE REVIEW FROM A QUATERNARY BRAIN TUMOUR CENTER IN CANADA2025